Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 1b Study to Evaluate the Safety, Efficacy and Mircobiological Response of Oral ABI-M201 in Subjects With Mildly-to-Moderately Active UC With Ongoing Mesalamine Treatment
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2021
Price :
$35
*
At a glance
- Drugs ABI M201 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Assembly Biosciences
- 17 Mar 2021 Status changed from recruiting to discontinued as per sponsor decision.
- 06 Oct 2020 Planned End Date changed from 1 Dec 2021 to 1 Mar 2023.
- 06 Oct 2020 Planned primary completion date changed from 1 Jun 2021 to 1 Aug 2022.